Navigation Links
The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies
Date:7/21/2014

availability. We forecast that acetylcholinesterase inhibitors (AChEIs) will continue to capture over 70 percent total patient share (across all AD subpopulations) in 2023, while NMDA receptor antagonist products, including Forest's Namenda/Namenda XR, will continue to capture approximately 35 percent patient share.

Comments from Decision Resources Group Analyst Alana Simorellis, Ph.D.:

  • "The projected launch of Eli Lilly's solanezumab, potentially the first ever DMT approved for the treatment of AD, will be a transformative event affecting the AD market as early as 2018. Commensurate with ongoing development and the views of experts in the field, we expect that future DMTs will most likely see the greatest uptake in the pre-AD and mild AD populations. Moreover, experts interviewed note that new symptomatic options also are sorely needed. Lundbeck/Otsuka's Lu-AE58054 and potentially others could partially address this need beginning in 2017."
  • "While AD drug development is understandably focused on disease modification, there exists an important area of additional unmet need for safer, more-effective symptomatic therapies that can control the behavior disturbances associated with later-stage AD. Development in this arena is underway, with clinical trials assessing promising agents like Lundbeck/Otsuka's brexpiprazole for AD-associated agitation."

*Decision Resources Group defines its proprietary pre-AD 1-2 years population as those patients who will go on to develop AD within the next one to two years.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
2. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
3. New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimers Disease
4. New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimers Disease
5. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
6. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
7. Pain Management Medical Journal Features BioElectronics Innovative Pain Products Because Pain is Not a Druggable Disease
8. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
9. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
10. Asleep During Brain Surgery: A Comfortable Alternative for Patients with Parkinsons Disease
11. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
(Date:9/30/2014)... MARIETTA, Ga. , Sept. 30, 2014 ... leading regenerative medicine company utilizing human amniotic tissue and ... therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports ... Dr. Tom Koob , Ph.D., Chief Scientific Officer, ... Mesa. Dr. Koob will present on Tuesday, October 7, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2MiMedx to Present at the Stem Cell Meeting on the Mesa 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... At the 10th Asian Forum on Corporate Responsibility ... and its philanthropic foundation the Abbott Fund were honored ... advancing science education in the region.  Abbott Science Education ... innovative events designed to spark an interest in life-long ...
... Mass. and TORONTO, Oct. 24, 2011 Generex Biotechnology ... the Company is planning an investor update conference call ... to provide investors with an update on (i) the ... previously announced spinout of its wholly-owned immunotherapeutics subsidiary, Antigen ...
Cached Medicine Technology:Abbott Honored With Asian CSR Award for Leadership in Science Education 2Abbott Honored With Asian CSR Award for Leadership in Science Education 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... Adelaide have developed a model that could help to ... treatment - from their very first psychotic episode. , ... including clinical symptoms, cognitive abilities, MRI scans of the ... Speaking in the lead up to World Mental Health ... , Professor Bernhard Baune , says the model ...
(Date:10/1/2014)... study published today in the Journal of the ... than 50 years with moderate or severe chronic knee ... from the University of Melbourne randomly assigned 282 patients ... no acupuncture or sham or pretend laser treatment. ... and acupuncturists blinded to laser and sham (inactive) laser ...
(Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... but critics want agency to act, not wait years ... ads on television should include a toll-free phone number ... U.S. health experts suggested Friday. , The experts serve ... Drug Administration. Such phone numbers are already mandated by ...
... Workers, WASHINGTON, May 16 More than ... Portland, Oregon and,Vancouver, Washington area have ratified their ... that these workers are now covered by a,strong ... secure retirement,future," said Teamsters General President Jim Hoffa., ...
... benefit from calcitriol, an oral form , , FRIDAY, May 16 ... risk of death for people with moderate to severe chronic ... , During a two-year study of more than 1,400 ... activated vitamin D, had their overall risk of death lowered ...
... what did you,say?" is a phrase being used more ... Americans, that is 1 in 9 individuals, have,significant hearing ... rate.,Thirteen out of every 100 school age children have ... attention to this social and economic problem,is what led ...
... for May 19 at 10:15 a.m. Eastern Time, ... (TSX: RBM, OTCBB: RPBIF) today announced that S. ... at the Rodman & Renshaw,5th Annual Global Healthcare ... A live web cast of the presentation ...
... needs is more unemployed politicians - and economists, ... health care at the top of their "most-important issues" ... health care plans,advanced by any of the current presidential ... U.S. Senate Majority Leader Bill Frist., Jousting with ...
Cached Medicine News:Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3
Inquire...
Inquire...
Inquire...
Inquire...
Medicine Products: